Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
|Articles|June 1, 2016
- Pharmaceutical Executive-06-01-2016
- Volume 36
- Issue 6
Pharmaceutical Executive, June 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive June 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 10 years ago
Pharm Exec's Top 50 Companies 2016over 10 years ago
Diversity and Inclusion: A Pharma 50 Perspectiveover 10 years ago
Design that Deliversover 10 years ago
A Digital Prescription for the Pharma Industryover 10 years ago
Science Meets Art: Mapping the Topography of MSover 10 years ago
Pharma and Biotech Financial Outlook: Hazyover 10 years ago
Promises and Pitfalls in Calculating Drug Valueover 10 years ago
Europe’s ‘Radical’ Regulators Drawn Further into Pricing Debateover 10 years ago
Country Report: ItalyAdvertisement
Related to this article
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Viatris is acquiring Pacira BioSciences for $1.65 billion in cash, adding non-opioid pain therapies Exparel and Zilretta.
Ultragenyx is selling it's Rare Pediatric Disease Priority Review Voucher earned for Genglycos’s approval for $210 million.
Pharma logistics are overqualified by design — and how agentic AI can now optimize across thousands of lanes in days, not months.
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.
ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
3
ESC 2026: GLP-1–Based Therapies Move Further into Mainstream Cardiovascular Care
4
Before You Sign with a New Hub Vendor, Ask These Four Questions
5